Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SCOLR updates

This article was originally published in The Tan Sheet

Executive Summary

UPM Pharmaceuticals has agreed to manufacture SCOLR Pharma's controlled delivery technology (CDT) 24-hour OTC pseudoephedrine, SCOLR announces June 6. The Bellevue, Wash.-based firm says it plans to use the UPM-produced PSE tablets in studies to support an NDA, to be submitted to FDA in 2006. UPM also will produce several of SCOLR's other products currently in development, including CDT 12-hour ibuprofen, 12-hour pseudoephedrine and a CDT-based osteoporosis drug raloxifene (Eli Lilly's Evista). Clinical testing has already been initiated for the 12-hour ibuprofen, the company reports...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS098316

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel